You are viewing: Japan Insulin Delivery Device Market analysis
Part of: Insulin Delivery Device Market (Global)

The Japan Insulin Delivery Device Market was valued at $295.1 Million in 2025 and projected to reach to $394.3 Million by 2030, representing a compound annual growth rate of 6.0%. Japan's insulin delivery device market is positioned for steady expansion through 2030, driven by the nation's aging population and increasing diabetes incidence rates.

Japan Insulin Delivery Device Market (2025-2030) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

Japan Insulin Delivery Device Market Trends and Insights

  • Japan's aging population and rising prevalence of diabetes are driving demand for advanced insulin delivery solutions, including pens, pumps, and syringes.
  • The market in Japan benefits from strong healthcare infrastructure, high patient awareness, and robust reimbursement policies that support adoption of modern delivery devices. The insulin delivery device market in Japan is characterized by steady growth driven by technological innovation and increasing preference for user-friendly, minimally invasive delivery systems.
  • Japan's emphasis on precision medicine and quality-of-life improvements for diabetic patients continues to fuel market expansion.
  • Between 2025 and 2030, Japan is expected to see sustained demand for insulin pens and continuous subcutaneous insulin infusion (CSII) pumps, supported by favorable demographic trends and healthcare investments..

Key Market Statistics

  • CAGR (2025-2030) 6.0% CAGR
  • Market Size, 2025 ~USD 295.1 Million
  • Forecast, 2030 ~USD 394.3 Million
  • Country Japan

Japan Insulin Delivery Device Market Overview

Aging Population Driving Demand :

Japan's rapidly aging demographic, with over 29% of the population aged 65+, is significantly increasing diabetes prevalence and creating sustained demand for insulin delivery devices across geriatric patient segments.

Advanced Healthcare Infrastructure :

Japan's world-class healthcare system, high insurance coverage rates, and strong reimbursement policies for diabetes management devices support widespread adoption of premium insulin delivery solutions including automated pumps and smart pens.

Steady Market Growth at 6% CAGR :

The Japanese insulin delivery device market is projected to grow from USD 295.1 million in 2025 to USD 394.3 million by 2030, outpacing many developed markets due to consistent healthcare investment and patient compliance.

Innovation in Delivery Technologies :

Japanese manufacturers and distributors are increasingly focusing on user-friendly, connected insulin delivery devices with digital health integration, catering to tech-savvy patients and healthcare providers seeking improved glycemic control.

Japan Insulin Delivery Device Market Dynamics

  • The market benefits from Japan's robust healthcare infrastructure, high patient awareness, and strong government support for chronic disease management.
  • Healthcare providers are increasingly adopting advanced insulin delivery systems to improve patient outcomes and reduce long-term complications. The competitive landscape in Japan is characterized by both established global manufacturers and innovative local players introducing next-generation devices.
  • Reimbursement policies remain favorable, and digital health integration is becoming a key differentiator.
  • As Japan continues to prioritize preventive healthcare and personalized medicine, the insulin delivery device market will likely see accelerated adoption of smart pumps and connected pen devices among both Type 1 and Type 2 diabetes patients..

Market Ecosystem

logo-mobile

INSULIN DELIVERY DEVICES MARKET: COMMERCIAL USE CASES ACROSS INDUSTRIES

COMPANY USE CASE DESCRIPTION BENEFITS
company logo
Novo Nordisk's insulin delivery portfolio includes reusable pens such as NovoPen 6 and NovoPen Echo Plus, as well as prefilled disposable pens such as FlexPen and FlexTouch. These devices are used by patients requiring insulin injections for diabetes management in home healthcare settings and under healthcare-professional supervision. Smart pens record dose information, while dose-setting mechanisms and prefilled designs simplify insulin administration. Supports accurate and convenient insulin administration, simplifies dose selection, and improves visibility into previous injections through connected or memory-enabled pens. Prefilled and reusable options accommodate different patient preferences and treatment requirements.
company logo
embecta provides insulin pen needles, conventional insulin syringes, and safety-engineered injection products. Its portfolio includes Nano pen needles, Ultra-Fine pen needles, AutoShield Duo safety pen needles, and insulin syringes in different needle lengths and barrel capacities. These products support subcutaneous insulin administration by patients at home and healthcare professionals in clinical settings. Offers flexibility in insulin administration through different needle lengths and syringe capacities. Shorter pen needles support a more comfortable injection experience, while safety-engineered products help reduce the risk of accidental needlestick injuries.
company logo
Medtronic's MiniMed insulin pump portfolio includes the MiniMed 780G automated insulin delivery system. The system uses continuous glucose monitoring data to adjust insulin delivery and provide automated correction doses. It is designed for eligible people with diabetes requiring insulin and is used in home-based diabetes management with healthcare-professional guidance. Enables personalized, continuous insulin delivery and automated adjustments based on glucose readings. Integration with glucose sensors can help improve glucose management, reduce the burden of multiple daily injections, and provide patients and care partners with access to diabetes-related information.
company logo
Sanofi offers insulin delivery devices associated with its insulin portfolio, including the SoloStar prefilled disposable pen and reusable pen options such as AllStar and TouStar in India. These devices are used to administer compatible insulin formulations, including Lantus, Toujeo, and Apidra in applicable presentations and markets. They support routine insulin administration for patients with diabetes in home and clinical settings. Provides prefilled and reusable delivery options to accommodate different treatment needs. Features such as dose selection, portability, and a prefilled format can simplify insulin administration and support convenient diabetes management. Device and insulin compatibility varies by product and market.
company logo
Eli Lilly supplies insulin in prefilled delivery devices, including the KwikPen platform used with products such as Humalog, Humulin, and Lyumjev in applicable markets. These pens enable patients requiring insulin therapy to administer prescribed doses through subcutaneous injection, including in home-based settings. Product-specific presentations and indications vary by country. Provides a convenient, prefilled insulin administration format with dose-selection features that can simplify routine injections. Multiple insulin formulations and pen presentations support different prescribed treatment requirements and help patients manage insulin administration outside healthcare facilities.

Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.

Related Ecosystem

Drug Delivery Devices

Top Technologies
  • Disposable Autoinjectors
  • Reusable Autoinjectors
  • Insulin Pumps
  • Pen Injectors
  • Transdermal Patches
Top Companies
  • Becton, Dickinson and Company
  • Novo nordisk a/s
  • Terumo Corporation
  • Medtronic plc
  • Nipro Corporation

    Medical Devices

    Top Technologies
    • Polymerase Chain Reaction (PCR)
    • Magnetic Resonance Imaging (MRI)
    • Disposable Autoinjectors
    • Pulse Oximeters
    • Blood Pressure Monitors
    Top Companies
    • Medtronic plc
    • Abbott Laboratories
    • Stryker Corporation
    • Becton, Dickinson and Company
    • JOHNSON & JOHNSON

      Key Takeaways

      • Japan's insulin delivery device market is valued at USD 295.1 million in 2025 and will reach USD 394.3 million by 2030, growing at 6.0% CAGR.
      • Japan's aging demographic and high diabetes prevalence are primary drivers of insulin delivery device adoption and market growth.
      • Japan's robust healthcare infrastructure and reimbursement policies support widespread adoption of advanced insulin delivery technologies.
      • Insulin pens and CSII pumps are the dominant device types in Japan, driven by patient preference for convenience and ease of use.

      Insulin Delivery Device Market Report Scope

      Report Metric Details
      Base Year 2025
      Fastest Growing Segment INSULIN PUMPS (Type)
      Forecast Period 2025–2030
      Growth Rate CAGR of 8.3% from 2025 to 2030
      Largest Segment TYPE 2 DIABETES (Disease Type)
      Market Size Base Year (Billions) ~USD 35.37 (2025)
      Revenue Forecast (Billions) ~USD 52.7 (2030)
      Segments Covered Type, Disease Type, End User

      Japan Insulin Delivery Device Market Report Segmentation

      3 segment dimensions are covered across the global market.

      By Type

      • Disposable Insulin Pens
      • Insulin Pen Needles
      • Insulin Pens
      • Insulin Pumps
      • Insulin Syringes
      • Other Insulin Delivery Devices
      • Reusable Insulin Pens
      • Safety Insulin Pen Needles
      • Standard Insulin Pen Needles
      • Tethered Insulin Pumps
      • Tubeless Insulin Pumps

      By Disease Type

      • Type 1 Diabetes
      • Type 2 Diabetes

      By End User

      • Home Care Settings
      • Hospitals & Clinics
      • Other End Users

      JAPAN: INSULIN DELIVERY DEVICES MARKET, BY END USER, 2025–2030

      Segment202520262027202820292030CAGR (%)
      HOME CARE SETTINGS1021.91106.61201.41307.61426.91514.58.2
      HOSPITALS & CLINICS385.1410.3438.2469.2503.7525.86.4
      OTHER END USERS77.182.989.396.5104.5110.17.4
      TOTAL1484.11599.71728.91873.32035.12150.47.7

      Target Audience

      • Medical Device Manufacturers : Manufacturers need Japan-specific market data to develop localized product strategies, understand competitive positioning, and identify opportunities for market entry or expansion in this high-value healthcare market.
      • Healthcare Distributors & Retailers : Distributors require detailed market insights to optimize inventory management, forecast demand by device type, and identify growth segments within Japan's insulin delivery device market for strategic partnerships.
      • Pharmaceutical Companies : Pharma firms need comprehensive market analysis to align insulin delivery device portfolios with market trends, support sales force training, and develop integrated treatment solutions for Japanese patients.
      • Healthcare Investors & Consultants : Investment professionals and management consultants require Japan-specific market data to evaluate investment opportunities, assess market attractiveness, and support due diligence for healthcare sector transactions.
      • Hospital & Clinic Administrators : Healthcare facility leaders need market insights to make informed procurement decisions, benchmark device adoption rates, and optimize diabetes management programs aligned with Japan's healthcare standards.

      Key Companies in the Japan Insulin Delivery Device Market

      CompanyHQOwnershipStrongest segments
      KINDRED HEALTHCARE INC.United StatesPrivate CompanyInjectable and infusion-based therapies in long-term acute care hospitals,Oral therapies in inpatient rehabilitation facilities,Contract rehabilitation and ancillary sites using mixed delivery routes,
      F5 NETWORKSUnited StatesPublic CompanyBIG-IP Systems and Packaged Software,NGINX (Plus, One Console, Ingress, WAF),Distributed Cloud Services (WAAP, Multi-cloud Networking, CDN, DNS),
      DIALOG SEMICONDUCTOR PLCUnited KingdomPrivate CompanyCustom Mixed Signal (PMICs, battery management, display power, motor control),Advanced Mixed Signal (configurable ICs, AC/DC, LED and SSL drivers),Connectivity & Audio (BLE, Wi-Fi SoCs, audio CODECs),

      KINDRED HEALTHCARE INC.

      Kindred Healthcare Inc. is a United States-based private company founded in 1985 that operates as a major healthcare services provider. With 64,200 employees, the company delivers a range of healthcare services across multiple care settings.

      F5 NETWORKS

      F5 Networks is a publicly traded United States company founded in 1996 with 6,545 employees that specializes in application delivery networking and security solutions.

      DIALOG SEMICONDUCTOR PLC

      Dialog Semiconductor PLC is a United Kingdom-based private company founded in 1998 with 2,300 employees that develops semiconductor solutions.

      Reasons to Buy this Report

      • Precise Japan-Specific Market Sizing : Access validated market data exclusive to Japan with accurate 2025 baseline (USD 295.1M) and 2030 forecast (USD 394.3M), enabling precise budget allocation and revenue projections for Japan operations.
      • Demographic Insights for Targeting : Understand Japan's unique aging population dynamics and diabetes prevalence patterns to identify high-value patient segments and tailor product positioning for maximum market penetration in this critical demographic.
      • Competitive Landscape Intelligence : Gain detailed analysis of Japan's competitive environment, including local and international players, market share distribution, and differentiation strategies specific to the Japanese healthcare ecosystem.
      • Reimbursement & Regulatory Guidance : Navigate Japan's complex healthcare reimbursement system and regulatory requirements with expert insights on insurance coverage, pricing strategies, and compliance pathways for insulin delivery devices.
      • Growth Opportunity Identification : Identify emerging opportunities in Japan's 6% CAGR market, including underserved patient segments, technology adoption gaps, and distribution channel expansion potential through comprehensive market analysis.

      Frequently asked questions

      What is the current size of the insulin delivery device market in Japan?

      The insulin delivery device market in Japan is valued at USD 295.1 million in 2025.

      What is the projected market size for insulin delivery devices in Japan by 2030?

      Japan's insulin delivery device market is projected to reach USD 394.3 million by 2030.

      What is the growth rate of the insulin delivery device market in Japan?

      The insulin delivery device market in Japan is expected to grow at a compound annual growth rate (CAGR) of 6.0% from 2025 to 2030.

      What factors are driving growth in Japan's insulin delivery device market?

      Key growth drivers in Japan include an aging population, rising diabetes prevalence, strong healthcare infrastructure, high patient awareness, and favorable reimbursement policies.

      Which insulin delivery devices are most popular in Japan?

      Insulin pens and continuous subcutaneous insulin infusion (CSII) pumps are the dominant device types in Japan due to their convenience and ease of use.

      RESEARCH METHODOLOGY

      The study focused on estimating the current market size for the insulin delivery devices sector. Extensive secondary research was conducted to gather information about the insulin delivery devices industry. The next step involved validating the findings, assumptions, and estimates through primary research with industry experts across the value chain. Various approaches were used to estimate the total market size, including top-down and bottom-up methods. Next, market segmentation and data triangulation procedures were used to determine the sizes of the segments and subsegments within the insulin delivery devices market.

      Secondary Research

      The secondary research process relies heavily on secondary sources, including directories and databases such as Bloomberg Businessweek, Factiva, and D&B Hoovers. It also includes white papers, annual reports, investor presentations, company SEC filings, and publications from government sources. Notable examples include the National Institutes of Health (NIH), the U.S. Food and Drug Administration (FDA), the U.S. Census Bureau, the World Health Organization (WHO), the International Trade Administration (ITA), the Global Burden of Disease Study, and the Centers for Medicare and Medicaid Services (CMS). These sources were utilized to gather information for the global insulin delivery devices market study. The process aimed to provide insights into key players, market classification, and segmentation based on industry trends, down to the most detailed level. It also focused on significant developments from both market and technological perspectives. A comprehensive database of key industry leaders was also created using the information obtained through secondary research.

      Primary Research

      In this report's primary research, we interviewed sources from both the supply and demand sides to gather qualitative and quantitative information. The supply-side primary sources included industry experts such as CEOs, vice presidents, marketing and sales directors, technology and innovation directors, and other key executives from major companies and organizations in the insulin delivery devices market. On the demand side, primary sources included pharmaceutical companies, vaccination centers, hospitals and clinics, pharmacies, and university researchers and academics. This primary research was conducted to validate the market segmentation, identify key players, and gather insights on significant industry trends and market dynamics.

      Insulin Delivery Devices Market 
 Size, and Share

      Note 1: C-level primaries include CEOs, CFOs, COOs, and VPs.
      Note 2: Others include sales managers, marketing managers, business development managers, product managers, distributors, and suppliers.

      Note 3: Companies are classified into tiers based on their total revenue. As of 2024, Tier 1 = >USD 10.00 billion, Tier 2 = USD 1.00 billion to USD 10.00 billion, and Tier 3 = <USD 1.00 billion.

      To know about the assumptions considered for the study, download the pdf brochure

      Market Size Estimation

      For the global market value, annual revenues were calculated based on the revenue mapping of major product manufacturers and OEMs active in the global insulin delivery devices market. All the major product manufacturers were identified at the global and/or country/regional level. Revenue mapping for the respective business segments/subsegments was done for the major players. Also, the global insulin delivery devices market was split into various segments and subsegments based on:

      • List of major players operating in the products market at the regional and/or country level
      • Product mapping of various insulin delivery device manufacturers at the regional and/or country level
      • Mapping of annual revenue generated by listed major players from insulin delivery devices (or the nearest reported business unit/product category)
      • Extrapolation of the revenue mapping of the listed major players to derive the global market value of the respective segments/subsegments
      • Summation of the market value of all segments/subsegments to arrive at the global insulin delivery devices market

      The above data was consolidated and added with detailed inputs and analysis from MarketsandMarkets and presented in this report.

      Insulin Delivery Devices Market Top Down and Bottom Up Approach

      Data Triangulation

      After determining the overall size of the global insulin delivery devices market using the methodology above, this market was split into several segments and subsegments. Where applicable, the data triangulation and market breakdown procedures were employed to complete the overall market engineering process and arrive at the exact market value data for the key segments and subsegments. The extrapolated market data were triangulated by analyzing macro indicators and regional trends from both demand- and supply-side participants

      Market Definition

      Insulin delivery devices are medical devices designed to deliver insulin, a hormone used to manage diabetes, into the body. These devices are primarily used by individuals with diabetes who require insulin therapy to regulate their blood sugar levels. Insulin pens, pumps, pen needles, and syringes are the most widely used delivery devices.

      Key Stakeholders

      • Manufacturing companies of insulin pen needles, insulin pens, insulin pumps, insulin syringes, injectable insulin delivery devices, and diabetes supplies
      • Suppliers and distributors of insulin pen needles, insulin pens, insulin pumps, insulin syringes, injectable insulin delivery devices, and diabetes supplies
      • Pharmaceutical and biopharmaceutical companies
      • Healthcare service providers
      • Teaching hospitals and academic medical centers
      • Health insurance players
      • Government bodies/municipal corporations
      • Regulatory bodies
      • Medical research institutes
      • Business research and consulting service providers
      • Venture capitalists
      • Market research and consulting firms

      Report Objectives

      • To describe, analyze, and forecast the global insulin delivery devices market based on type, end user, and region
      • To describe and forecast the insulin delivery devices market for key regions, namely, North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa
      • To provide detailed information regarding the drivers, restraints, opportunities, and challenges influencing the growth of the insulin delivery devices market
      • To strategically analyze the ecosystem, regulations, patenting trends, value chain, Porter’s five forces, and prices of the market under study
      • To strategically analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall market
      • To analyze market opportunities for stakeholders and provide details of the competitive landscape for market players
      • To profile the key players and comprehensively analyze their market shares and core competencies in the insulin delivery devices market
      • To analyze competitive developments such as partnerships, collaborations, acquisitions, product launches, expansions, and R&D activities in the insulin delivery devices market
      • To benchmark players within the market using the proprietary Company Evaluation Matrix framework, which analyzes market players on various parameters within the broad categories of business and product strategy.

      Available customizations:

      Based on the market data, MarketsandMarkets offers customizations to meet your company’s needs. The following customization options are available for the report:

      GEOGRAPHIC ANALYSIS

      • Further breakdown of the Rest of Europe’s insulin delivery devices market into Switzerland, Denmark, and Austria, among others
      • Further breakdown of the Rest of Asia Pacific’s insulin delivery devices market into Vietnam and Taiwan, among others
      • Further breakdown of the Rest of Latin America’s insulin delivery devices market into Argentina, Colombia, Chile, and Ecuador
      • Further breakdown of the Southeast Asia insulin delivery devices market into Malaysia, Singapore, Australia, and New Zealand

      COMPETITIVE LANDSCAPE ASSESSMENT

      • Market share analysis by region (North America and Europe), which provides market shares of the top 3–5 key players in the insulin delivery devices market
      • Competitive leadership mapping for established players in the US

       

      Get the Full Insulin Delivery Device Market Report

      Full forecast, segment splits, and company analysis for all Insulin Delivery Device Market.

      Need a Tailored Report?

      Customize this report to your needs

      Get 10% FREE Customization

      Customize This Report
      Fact checked
      DMCA.com Protection Status